Obtenga las últimas noticias sobre las acciones de Armata Pharmaceuticals con actualizaciones sobre las tendencias del mercado, las finanzas y el análisis de Benzinga. Manténgase informado sobre el rendimiento de ARMP

Últimas noticias sobre

ARMATA PHARMACEUTICALS INC

Armata Pharmaceuticals

Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.

Section,Of,A,Financial,Newspaper,Titled,Key,Movers

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AIRE

AMZN

ARMP

BATL

BENF

BNBX

JWEL

QBTS

RBNE

SGBX

Brera Holdings PLC - Class B Ordinary Shares

SLMT

TSLA

VTYX

YDKG

Resumen de las acciones en alza y baja durante el premercado de EE. UU., con movimientos destacados en tecnología, energía y biotecnología.

Acciones de LendingClub suben alrededor del 13%; Aquí están 20 acciones que se mueven en el premercado

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals Inc

Press Releases

Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02

Earnings

Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update

Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia

This $13M Biotech Has $40M in Pentagon Funding – Here's Why BiomX Could Be Biotech's Best-Kept Secret

Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update

Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology

Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™

Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™

Personal Finance

Could the Next Breakthrough in Antibiotic Resistance Come From Viruses That Kill Bacteria?

PHGE

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics

Alector

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics

Perspective Therapeutics, Inc. Common Stock

Perspective Therapeutics

Compugen

Coherus Oncology

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals

Cardiff Oncology

Citius Oncology

Elicio Therapeutics

Fate Therapeutics

Forte Biosciences

Genfit

Heron Therapeutics

Insight Molecular Diagnostics Inc. - Common Stock

Insight Molecular

Innate Pharma S.A. - American Depositary Shares

Innate Pharma

Seres Therapeutics

Nkarta

Nuvectis Pharma

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

Pyxis Oncology

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics

Vor Biopharma

HC Wainwright & Co.

Axovant Gene Therapies Ltd. - Common Shares

Comments

Armata Pharmaceuticals Noticias bursátiles

Noticias

Últimas noticias sobre

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL